Category: Business

Iconic Sports Brand Donates to Equestrian and Polo Charities Chosen by the Finalists

WEST PALM BEACH, Fla., March 8, 2023 (Newswire.com)
–
U.S. Polo Assn., the official brand of the United States Polo Association (USPA), celebrates International Women’s Day on March 8, the globally celebrated day dedicated to economic, social and gender equality for women, alongside the 2023 U.S. Open Women’s Polo Championship^®. The most prestigious cup in women’s polo in the United States runs from March 10-19. 

U.S. Polo Assn.’s involvement with the most celebrated cup for women’s polo in the United States includes donations made to polo and equestrian charities selected by the finalists in the 2023 U.S. Open Women’s Polo Championship. 

The qualifying games will be played at Port Mayaca Polo Club, while the U.S. Open Women’s Polo Championship Final will be played once again at the world-renowned USPA National Polo Center (NPC) – Wellington on March 19. ESPN will distribute the Women’s Championship Final for sports fans around the globe, where it will be available on ESPN’s family of brands. Check your local listings for air times.

The 2023 U.S. Open Women’s Polo Championship is being played alongside International Women’s Day which honors women’s achievements around the world while challenging inequality and working to increase visibility for women. 

“Not only do these athletes exude incredible tenacity and strength on the field, but they also do off of the field. From lawyers, to entrepreneurs, to mothers, to movie producers, to students, to animal conservationists, and more, the contestants in this year’s Open fully show what a woman is capable of in their off-field endeavors,” said Meghan Gracida, USPA Women’s Committee Chair. “It is the great sport of polo that brings all of these women together to empower one another as players while exhibiting their love for the ultimate four-legged teammates—horses. I am honored to again be involved with this most special women’s polo event.”

Prominent players in this year’s high-goal tournament include Hope Arellano, Hazel Jackson, and Mia Cambiaso, to name a few.

“As a fourth-generation polo player, my love for the game started at a very young age and continues to provide opportunities for me to participate in top-rated polo tournaments, like the 2023 U.S. Open Women’s Polo Championship, which I am so grateful to be a part of,” said Hope Arellano, professional polo player and U.S. Polo Assn. Brand Ambassador. “I look forward to competing against incredibly talented women polo players and being surrounded by those in the South Florida polo community who support women’s professional polo.”

Unlike other team sports, women and men play polo together as equals, and approximately 40% of USPA club members are female. Women are, in fact, the fastest-growing segment in the sport of polo at the club level.

“The 2023 U.S. Open Women’s Polo Championship is both a celebration and showcase of women’s many polo achievements,” said J. Michael Prince, President and CEO of USPA Global Licensing, the worldwide licensor of the multi-billion-dollar U.S. Polo Assn. brand. “U.S. Polo Assn. continues to support the sport of polo and its players around the world both on and off the field, and this tournament highlights some of the very best female players in the sport.”

If you attend:

Who/What: U.S. Open Women’s Polo Championship Final

When:          Sunday, March 19, 2023

                      3:00 p.m. EDT Championship Final

Where:        U.S. Polo Assn. Stadium Field 

                      USPA National Polo Center, 3667 120th Ave. S, Wellington, Florida

To learn more or to purchase tickets, please click HERE.

About the U.S. Open Women’s Polo Championship™

The U.S. Open Women’s Polo Championship^® has a profound history dating back to the 1930s in California. The first women’s U.S. Open tournament was presented by the United States Women’s Polo Association (U.S.W.P.A) in 1937 at the Golden Gate Field in San Francisco, California. Women were officially welcomed into the United States Polo Association in 1972 with Sue Sally Hale becoming the first woman member. On the centennial anniversary of the USPA in 1990, a U.S. Women’s Open was officially sanctioned and held at Empire Polo Club in Indio, California. It was officially recognized as a national tournament in 2011 and has been hosted at the Houston Polo Club for the past seven years, becoming the largest annual women’s polo event in the United States.

About U.S. Polo Assn. 

U.S. Polo Assn. is the official brand of the United States Polo Association (USPA), the non-profit governing body for the sport of polo in the United States and one of the oldest sports governing bodies, having been founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through some 1,100 U.S. Polo Assn. retail stores and thousands of department stores as well as sporting goods channels, independent retailers and e-commerce, U.S. Polo Assn. offers apparel for men, women, and children, as well as accessories and footwear in more than 190 countries worldwide. U.S. Polo Assn. was named as one of the top five sports licensors in 2022, according to License Global. Visit uspoloassnglobal.com and follow @uspoloassn.

About the United States Polo Association® (USPA) 

The United States Polo Association was organized and exists for the purposes of promoting the game of polo, coordinating the activities of its Member Clubs and Registered Players, arranging and supervising polo tournaments, competitions and games, and providing rules, handicaps, and conditions for those tournaments, competitions, and games including the safety and welfare of participants and mounts. Founded in 1890, the USPA is the national governing body for the sport of polo. The USPA is currently comprised of almost 200 member clubs with thousands of individual members and oversees 40 national tournaments. For more information, please visit uspolo.org.

Contact Information:

Shannon Stilson

VP, Sports Marketing & Media

[email protected]

+001.561.227.6994

Stacey Kovalsky

Senior Director, Global Communications

[email protected]

+001.561.790.8036

Original Source:

U.S. Polo Assn. Celebrates International Women’s Day Alongside the 2023 U.S. Open Women’s Polo Championship Airing on ESPN

Sherwood Lumber: creating an impeccable Employee, Vendor and Customer Experience.

MELVILLE, N.Y., March 8, 2023 (Ne…

Leading innovator of lithium-ion cell technology Durapower partners with recycling leader TES to help achieve optimal outcomes for second-life deployment and end-of-life management of lithium-ion batteries
…

SYDNEY, March 7, 2023 (Newswire.com)
–
Parnell Pharmaceuticals Holdings Ltd (OTC: PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Thursday, April 6th 2023 at 8:30 a.m. (Australian Eastern Standard Time).

NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM

Notice is given that the Annual General Meeting of shareholders of Parnell Pharmaceuticals Holdings Ltd (Company) will be held on:

Thursday, April April 6th 2023 at 8:30 a.m. (Australian Eastern Standard Time)

The meeting is to be held in person at the Company’s headquarters: First Floor, Unit 4, 476 Gardeners Road, Alexandria NSW, 2015, Australia

For a link to the full Notice of Annual General Meeting and Explanatory Memorandum please click: 

https://cdn.newswire.com/files/x/06/4e/973f63370a45ad06e2bcb4d2b55f.pdf

_________________________________

28 February 2023

Dear Shareholder,

On behalf of the Board of Directors of Parnell Pharmaceuticals Holdings Limited (ACN 137 904 413) (Company), I invite you to join us at our Annual General Meeting (AGM), which has been scheduled as follows:

Date: Thursday, April 6th 2022 (AEST)
Time: 8:30 a.m. (AEST)
Venue: Held by physical attendance at: First Floor, Unit 4 Century Estate, 476 Gardeners Road, Alexandria, NSW, 2015

Outline of the business of the GM

At this GM, we will consider whether to approve the buying back of shares in the Company (“Shares”) owned by Mr Robert Joseph and Mrs Kate Joseph, pursuant to a Settlement and Mutual Release Agreement recently made by the Company with Mr and Mrs Joseph.

Details of this business are contained in the enclosed Notice of GM and Explanatory Memorandum.

Voting at the GM or by proxy

A proxy form accompanies the enclosed Notice of GM. If you wish to attend the GM in person, please bring a copy of the proxy form with you. Registration will be available from [time] (AEST). If you are unable to attend in person, I encourage you to appoint a proxy to vote on the resolutions contained in the Notice of GM on your behalf, by completing and returning the enclosed proxy form. Details of how to submit the proxy form are included with the form.

If you have any difficulties placing your vote via proxy please do not hesitate to contact Brad McCarthy at [email protected] or call +612 9667 4411.

On behalf of all of the Directors, we look forward to hearing from you at the AGM.

Yours sincerely,

Alan Bell
Chairman

Related Files
Parnell Notice of General Meeting and Ex Mem (Buy-Back) – Final (Apr’23).pdf

Original Source:

Parnell Pharmaceuticals Gives Notice of Annual General Meeting and Explanatory Memorandum

Combining Creative Forces for Good.

LEAWOOD, Kan., March 7, 2023 (Newswire.com)
–
DEMDACO, a leading gi…

Switch Takes ‘Accessible Luxury’ to a New Level by Launching Luxury Handbags as Part of Its Core Membership

LOS ANGELES, March 7, 2023 (Newswire.com)
–
Luxury accessory rental startup Switch has launched handbags as part of its low-priced Core membership tier. Until now, Switch’s Core membership exclusively featured jewelry. The expansion means that members will be able to borrow designer handbags by luxury fashion brands including Chanel, Louis Vuitton, and Christian Dior for $45 per month.

While other luxury rental services have emerged in recent years, none have offered access to luxury handbags at such a low price point. The move highlights Switch’s ambition to make luxury more attainable.

“Switch is all about challenging traditional notions of luxury,” said Adriel Darvish, Co-Founder and CEO of Switch. “By adding handbags to our Core membership, our goal is to make the luxury experience, which has traditionally been hyper-exclusive and intimidating, more inclusive and fun.”

The move follows the wildly successful rollout of its higher-end tier Switch Select at the end of last year. Select features jewelry and handbags with an average retail value of $4,000, which members can borrow for $195 per month. Because of the continued high demand, aspiring Select members must sign up for a waitlist, from which members are admitted on a rolling basis.

“The success of our Select membership has highlighted the immense demand for luxury handbags,” added Switch President and co-founder Liana Kadisha Cohn. “Once we saw that customer interest, we quickly responded by making it a part of our Core offering as well.”

All Switch plans allow members to borrow their pieces for as long as they want, exchange them as often as they want, and purchase their favorites at a discounted price.

ABOUT SWITCH

Switch is on a mission to revolutionize luxury by providing unparalleled access to designer accessories. For a monthly fee starting at $45/month, members can borrow from an ever-expanding trove of designer jewelry and handbags and exchange it any time, as often as they wish. Members also earn credit each month, which they can use towards purchasing their favorites at a discount. Switch is the grown-up’s dress-up trunk — a place for play, discovery, and owning your style (albeit not literally). 

Contact Information:

Natallie Mashian

Head of PR and Partnerships

[email protected]

(310) 666-0641

Original Source:

Switch Introduces Handbag Rentals From $45/Month

Viirtue Raises $10.8M Series A Fundraising from Ballast Point Ventures

TAMPA, Fla., March 7, 2023 (Newswire.com)
–
Viirtue (viirtue.com), an award-winn…

Microsoft MVP Ryan Clark and VirtoSoftware Join Forces to Deliver Seamless Customer Experience

VirtoSoftware and Microsoft MVP Ryan Clark Partnersh…

Biopharmaceutical research company specializing in cannabis- and plant-inspired medicines shares strategic plan for 2023 and key developments from 2022

LAS VEGAS, March 7, 2023 (Newswire.com)
–
Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, issued a letter to shareholders today from President, Chief Science Officer, and Director Dr. Andrea Small-Howard and Chairman and CEO John Poss summarizing key developments from 2022 and providing strategic plans for 2023. Full text of the shareholder letter follows.

A MESSAGE FROM BOTH THE PRESIDENT AND THE CHAIRMAN OF GB SCIENCES, INC.

To Our Shareholders:

In 2022, Gb Sciences achieved significant milestones advancing our plant-inspired drug development pipeline for the treatment of a broad spectrum of critical and prevalent diseases, which supports the value of PhAROS™, our proprietary AI-enabled Drug Discovery Platform. Gb Sciences is entering 2023 with very good reason for excitement and optimism for our shareholders and for the potential to develop first-in-class drugs to treat serious disorders such as: Parkinson’s Disease, Advanced Heart Disease, Chronic Pain, Inflammation, Anxiety and Depression. In addition, our intellectual property portfolio currently contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications that cover our novel AI-enabled drug discovery platform and proprietary therapies for more than 65 different disorders. 

Recognizing the value of our PhAROS™ Drug Discovery Platform for expediting our novel plant-inspired drug pipeline, we also realize that PhAROS™ has the potential to be of high value to other drug development biotech and pharmaceutical companies. With its data analytics and machine learning capabilities providing a breakthrough in drug discovery, our PhAROS™ Drug Discovery Platform greatly reduces the time and money required to discover and bring novel formulations to market. Therefore, in addition to developing our own biopharma pipeline, we plan to monetize PhAROS™ by pursuing potential licensing and/or partnerships with other drug developers that offer the potential to generate substantial, recurring, high-margin revenues to Gb Sciences. 

While other drug developers pursue conventional drug pathways, Gb Sciences is developing novel Minimal Essential Mixtures derived from the active ingredients found within traditional plant-based medicines that are still commonly used across the world. Traditional medicines that are mostly plant based have been used for centuries and are composed of all the ingredients for specific plants which can number in the hundreds or even thousands. Gb Sciences uses our novel PhAROS™ Drug Discovery Platform to determine which three ingredients of the hundreds of ingredients found in each plant are the most effective and with the fewest adverse side effects.

In 2022, Gb Sciences has successfully prepared our lead program in Parkinson’s disease for a first-in-human trial through the following essential steps: a) creating clinical prototypes by combining our proprietary Parkinson’s formulas with a convenient oral delivery system; b) performing a dose response study in rodents to establish the correct range of active ingredients for our first-in-human trial; c) performing necessary ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicology) tests on the clinical prototypes; and d) selecting a Contract Research Organization (CRO) to prepare an Investigational New Drug (IND) application to the U.S. FDA to begin our first-in-human trial. 

Working with Catalent Pharma in 2022, Gb Sciences has successfully prepared the clinical prototypes of our proprietary cannabinoid-based formulations for Parkinson’s disease in Catalent Pharma’s proprietary Zydis® delivery system. Catalent Pharma’s Zydis® delivery system is an Orally Disintegrating Tablet format that should be ideal for delivering our cannabinoid-ratio controlled formulations to Parkinson’s patients. More than 50% of Parkinson’s patients have trouble swallowing, but the Zydis® format delivers the active ingredients into the mouth by dispersion without needing water or the ability to swallow. 

In February of 2023, the University of Lethbridge has successfully completed our dose response study in rodents, which helps us to establish the correct dosing of our cannabinoid-containing Parkinson’s formulations in our first-in-human trial. The results of this important study will be delivered to Gb Sciences from the University of Lethbridge within the next six weeks.

Prior to filing our IND application for our first-in-human trial on our Parkinson’s formulations, Gb Sciences must conduct ADMET testing on the clinical prototypes being formulated for us by Catalent Pharma. Gb Sciences has selected Labcorp Drug Development, formerly Covance, to perform our IND-enabling studies due to their expertise and testing locations in the United Kingdom near to where the ODT tablets are being manufactured by Catalent Pharma. 

In the IND application for our Parkinson’s disease therapeutics, the ADMET testing data from Labcorp will be combined with the Chemistry Manufacturing and Controls (CMC) data prepared by Catalent Pharma and our proof-of-concept data from the National Research Council (NRC) of Canada. In the near future, we expect to announce the selection of the Contract Research Organization that will write the IND application and run the first-in-human trials for our novel treatment for the motor symptoms of Parkinson’s disease.

Gb Sciences has four other promising late-preclinical stage programs, including our COVID-related cytokine release syndrome (COVID-CRS) formulations and our time-released oral nanoparticle formulations for chronic pain. We have achieved preclinical proof-of-concept for our COVID-CRS formulas in studies performed by Michigan State University. Our chronic pain formulations are being validated in animal trials at the National Research Council of Canada. Recently, we have announced that our kava-inspired formulas for anxiety have achieved animal proof-of-concept. Gb Sciences is now preparing its non-psychedelic, kava-based anxiety formulations to treat the growing global need for anxiety and depression relief.

In closing, we would like to thank those shareholders who have supported our company this year and in past years. Our goal remains to produce maximum shareholder value while also providing innovative new therapeutic options for patients that need them.

Sincerely,

Dr. Andrea Small-Howard
President, CSO & Director
Gb Sciences, Inc.

John Poss 
Chairman & CEO
Gb Sciences, Inc.

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The “plant-inspired” active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and four issued foreign patents, as well as 15 U.S. and 49 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:

Alexis Quintal

[email protected]

Original Source:

Successful 2022 Milestones Support Value of Gb Sciences’ AI-Enabled Drug Discovery Platform

Straits® LED Crane Warning Lasers illuminate a clear warning zone around overhead crane loads and other hazardous areas. This warning zone ensures compliance and protects pedestrians from potential accidents.
…